Caitlin Ryser, MD
Obstetrics & Gynecology · Warsaw, INNPI 1699718940
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 25.5% of the total. Reporting peaked in 2022 at $461 and has fallen 77.2% since, to $105 in 2024.
Across 80 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$330
- Pfizer$171
- Therapeuticsmd, Inc.$169
- Bayer$101
- Mayne Pharma Commercial LLC$96
- Exeltis, USA Inc.$74
- plus $351 from 11 others
What the payments were for
- Food & beverage$1,292100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $330 |
| Pfizer | 10 | $171 |
| Therapeuticsmd, Inc. | 11 | $169 |
| Bayer | 7 | $101 |
| Mayne Pharma Commercial LLC | 6 | $96 |
| Exeltis, USA Inc. | 4 | $74 |
| Shield Therapeutics Inc | 4 | $73 |
| Aspira Women's Health Inc | 1 | $54 |
| Astellas Pharma US Inc | 2 | $49 |
| Agile Therapeutics, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $33 |
| Biogen | 1 | $24 |
| Johnson & Johnson | 1 | $17 |
| Urovant Sciences Inc | 1 | $16 |
| Merck | 1 | $16 |
| Evofem Biosciences, Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $14 |
How this compares
$1,292 in reported general payments places this provider in the 60th percentile of 743 obstetrics & gynecology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 12 | $16,337 |
| Estradiol | 11 | $504 |
| Clobetasol Propionate | 19 | $477 |
| Solifenacin Succinate | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Warsaw
- Timothy CookWarsaw$12K
- Luis GonzalezWarsaw$8K
- Ashley ScottFort Wayne$124K
- Candace WestgateIndianapolis$123K
- Keith RamseyLake Station$116K
- Stefanie FloraCarmel$106K
- Lori DavidsonGreenwood$54K
- Julius Ellisla Porte$53K
- Emmary ButlerWinchester$45K
- Enrique InfanteElkhart$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.